Backs FY25 revenue view $1.11B-$1.16B, consensus $1.14B. Backs FY25 EBITDA view $140M-$155M. “As we progress through 2025, we remain focused on successfully executing on our strategic priorities and driving long-term revenue growth while striving to deliver the innovation and expertise that should help our customers achieve enhanced clinical and operational outcomes, as they seek to move closer to the industry-defined vision of the Autonomous Pharmacy,” Lipps said.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMC:
- Omnicom backs Q1 EPS view 15c-25c, consensus 21c
- X demands Interpublic to get clients to spend more money on platform, WSJ says
- Interpublic Group cut to Hold at Argus on concerns over Omnicom merger
- AMD downgraded, Roku upgraded: Wall Street’s top analyst calls
- Argus cuts Omnicom to Hold, sees Interpublic deal as ‘bit of a reach’
Questions or Comments about the article? Write to editor@tipranks.com